FDA Brief

Warning letters Drugs

FDA warning letter to

Amgen Inc.

MediumIssued Aug 12Posted Oct 27The Office of Prescription Drug Promotion (OPDP)

FDA says an Amgen promotional video for the cancer drug Vectibix is false and misleading because it leaves out all risk information.

What happened

FDA's Office of Prescription Drug Promotion reviewed a promotional video for Vectibix that Amgen submitted under Form FDA 2253, the filing companies use to send FDA promotional materials at the time they are first used. FDA found the video promotes benefits — short infusion time, no premedication, colon imagery — but gives no risk information at all, and does not spell out the approved regimens or limitations of use. FDA concluded the video is false or misleading and therefore misbrands Vectibix.

What FDA found

  1. The video promotes Vectibix's benefits but completely leaves out its risks, including the boxed warning for skin toxicity and risks such as infusion reactions, lung scarring and interstitial lung disease.

    21 U.S.C. 352(a), (n); 21 CFR 202.1(e)(3)(ii)
  2. The video does not disclose the limits on when Vectibix may be used — it is not indicated for RAS-mutant mCRC except with sotorasib in KRAS G12C-mutated disease, and not for patients whose RAS mutation status is unknown.

    21 U.S.C. 321(n); 21 CFR 202.1(e)(3)(iii)
  3. The video suggests Vectibix is a general treatment for wild-type RAS mCRC without saying which regimens and lines of therapy it is approved for.

    21 CFR 202.1(e)(3)(iii)
  4. Because of these omissions the video misbrands Vectibix, so distributing the drug with that promotion violates the law.

    21 U.S.C. 331(a); 21 CFR 202.1(e)(5)

What FDA wants

FDA tells Amgen to stop the misleading promotional communications immediately and to send a written response within 15 working days of receiving the letter. The response must list other Vectibix promotional communications with the same problems, explain the plan to discontinue them, and lay out a plan to send truthful corrective communications to the same audience.

Who should pay attention

  • regulatory and medical reviewers who sign off on prescription drug promotional materials
  • advertising agencies and vendors that produce pharma videos and promotional content
  • oncology marketers preparing promotional pieces for drugs with boxed warnings or narrow indications

This is a summary. Read the original letter on fda.gov.

Amgen Inc.'s FDA history

Recalls in the last 12 months

Jul 1 Class II Amgen, Inc.
Drug
Corlanor (ivabradine) tablets, 7.5mg, 60-count bottles, Rx Only, Amgen Inc., Thousand Oaks, CA 92130 Made In Italy. NDC 55513-810-60
Presence of Foreign Substance.
Jul 1 Class II Amgen, Inc.
Drug
Corlanor (ivabradine) tablets, 5 mg, packaged in a) 14 tablets bottles (NDC 55513-800-99), and b) 60 tablet bottles (NDC 55513-800-60), Rx Only, Amgen Inc., Thousand Oaks, CA 92130 Made In Italy.
Presence of Foreign Substance.
Jul 1 Class II Amgen, Inc.
Drug
Sensipar (cinacalcet) Tablets, 60mg, 30-count bottles, Rx Only, Distributed by: Amge, One Amgen Center Drive, Thousand Oaks ,CA 91320-1799, Made in Japan. NDC 55513-074-30
CGMP Deviations
Jul 1 Class II Amgen, Inc.
Drug
Sensipar (cinacalcet) Tablets, 90mg, 30-count bottles, Rx Only, Distributed by: Amge, One Amgen Center Drive, Thousand Oaks, CA 91320-1799, Made in Japan. NDC 55513-075-30
CGMP Deviations
Jul 1 Class II Amgen, Inc.
Drug
Sensipar (cinacalcet) Tablets, 30mg, 30-count bottles, Rx Only, Distributed by: Amge, One Amgen Center Drive, Thousand Oaks ,CA 91320-1799, Made in Japan. NDC 55513-073-30
CGMP Deviations

Full company page

Similar letters to other companies

  1. Stokes Healthcare Inc. dba Epicur Pharma

    FDA warned Epicur Pharma over website claims for compounded omeprazole and buprenorphine animal drugs that are false or misleading.

    High risk
  2. Herbal Dermals LLC FZ dba Gotucream

    FDA warned Herbal Dermals LLC FZ dba Gotucream that its Gotucream balanitis cream is an unapproved new drug.

    Low
  3. Nexus Health Solutions LLC dba Harper Meds

    FDA warned telehealth seller Harper Meds that its website misbrands compounded semaglutide and tirzepatide with false and misleading claims.

    Low
  4. Thrivelab Co. dba Thrivelab

    FDA warned telehealth seller Thrivelab that its website misbrands compounded semaglutide with false claims suggesting FDA approval.

    Medium